MARTIN ATTA: Open Payments
NPI 1811570005 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$449 in 21 payments from 6 companies in 2025. Trend: 2023 $142 · 2024 $133 · 2025 $449
Food & beverage: $449
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $142 |
| E.R. Squibb & Sons, L.L.C. | 4 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Neurocrine BioSciences, Inc. | 1 | $39 |
| Axsome Therapeutics, Inc. | 1 | $28 |
Products named: VRAYLAR, COBENFY, CAPLYTA, ABILIFY MAINTENA, INGREZZA, Auvelity, REXULTI.
Industry payments across MD — which companies pay providers there.
